One Step Up in Antiproliferative Activity: The Ru‐Zn Complex [RuCp(PPh₃)₂‐µ‐dmoPTA‐1κP:2κ²N,N′‐ZnCl₂](CF₃SO₃)

Abstract

The synthesis, characterization and antiproliferative activity of the bimetallic Ru-Zn complex [RuCp(PPh 3 ) 2 -μ-dmoPTA-1κP:2κ 2 N,N′-ZnCl 2 ](CF 3 SO 3 ) (4) and the monometallic Ru complex [RuCp(PPh 3 ) 2 (dmoPTA-1κP)](CF 3 SO 3 ) (5) are presented. Against human lung, cervix, breast, and colon solid tumor cell lines, complex 4 showed an enhanced antiproliferative activity (GI 50 = 30-83 nM) when compared to its parent complex [a]

New Findings in Metal Complexes with Antiproliferative Activity Containing 1,3,5‐Triaza‐7‐phosphaadamantane (PTA) and Derivative Ligands

“…[51] This compound was initially synthetized by a procedure similar to that used for previously described bimetallic complexes, but it was revealed to be not good enough as is very sensitive to reaction conditions. [51] This compound was initially synthetized by a procedure similar to that used for previously described bimetallic complexes, but it was revealed to be not good enough as is very sensitive to reaction conditions.…”

“…The last published example of this second generation of bimetallic compounds containing dmoPTA is the Ru‐Zn complex [RuCp(PPh 3 ) 2 ‐µ‐dmoPTA‐1κ P :2κ 2 N , N′ ‐ZnCl 2 ](CF 3 SO 3 ) ( 65 ) . This compound was initially synthetized by a procedure similar to that used for previously described bimetallic complexes, but it was revealed to be not good enough as is very sensitive to reaction conditions . A new synthetic procedure was designed from the complex [RuCp(PPh 3 ) 2 (1κ P ‐dmoPTA‐)](CF 3 SO 3 ) ( 63 ), which was synthetized by reaction of starting complex 63 with 1.1 equivalent of t ButOK in THF (Scheme ).…”

The Significant Influence of a Second Metal on the Antiproliferative Properties of the Complex [Ru(η6−C10H14)(Cl2)(dmoPTA)]

“…Among them, the bismetallic complex [RuCp(PPh 3 ) 2 ‐μ‐dmoPTA‐1κ P :2κ 2 N,N’ ‐ZnCl 2 ](CF 3 SO 3 ) showed the highest cytotoxicity against a panel of tumor cells (A549 (lung), HBL‐100 (breast), T‐47D (breast), SW1573 (lung), HeLa (cervix), WiDr (colon)), being 26–426 times more active than cisplatin. This complex also showed good selectivity for cancer cells as it displayed three times lower toxicity against the nontumor human cell line BJ‐hTert [17] . These results evidenced that the dimethylation of the PTA ligand and the further coordination of a metallic moiety to the Ru‐dmoPTA scaffold are key points for what concern the structure‐activity relationship (SAR) of this class of compounds.…”

Selective Anticancer and Antimicrobial Metallodrugs Based on Gold(III) Dithiocarbamate Complexes

“…Another important limitation of platinum drugs is the developing resistances shown by some kinds of tumors. For these reasons, other transition metals such as iron [ 5 ], copper [ 6 ], ruthenium [ 7 , 8 , 9 ], and gold [ 10 , 11 , 12 ], among others [ 13 ], have been considered as anticancer drugs and the results obtained in these studies are promising. The use of gold in medicine comes from its traditional use in medicine as antiarthritic agents such as gold(I) thiomalate (myocrisin), gold(I) thioglucose (solganol), and 2,3,4,6-tetra-o-acetyl-1-thio-b-D-glucopyranosato-(S)-triethylphosphine gold(I) (auranofin) ( Figure 1 ).…”